Patents by Inventor Rob FIELD

Rob FIELD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10174069
    Abstract: The invention provides methods and materials for use in the detection of influenza viruses which utilise a nanoparticle, for example gold nanoparticle, probe comprising a plurality of glycoconjugate ligands, each glyconjugate ligand (GL) having a plurality of sialic-acid containing recognition group (Y) coupled to the nanoparticle via a multivalent core (X), wherein the multivalent core (X) is a trivalent core, whereby there are 3 recognition groups per ligand, wherein the recognition groups on the bioconjugate specifically bind to the hemagglutinin on the target influenza virus. The probes may include further ligands bound to the nanoparticle which do not bind specifically to an influenza virus—for example polyethylene glycol groups. These can modulate density of the glycoconjugate ligand on the surface of the nanoparticle. Binding of probes is detected by a plasmonic signal which is specific to the influenza virus.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: January 8, 2019
    Assignee: ICENI DIAGNOSTICS LIMITED
    Inventors: Rob Field, Martin Rejzek, Abdul Rashid, David Andrew Russell, Maria Jose Marin Altaba
  • Publication number: 20160185814
    Abstract: The invention provides methods and materials for use in the detection of influenza viruses which utilise a nanoparticle, for example gold nanoparticle, probe comprising a plurality of glycoconjugate ligands, each glyconjugate ligand (GL) having a plurality of sialic-acid containing recognition group (Y) coupled to the nanoparticle via a multivalent core (X), wherein the multivalent core (X) is a trivalent core, whereby there are 3 recognition groups per ligand, wherein the recognition groups on the bioconjugate specifically bind to the hemagglutinin on the target influenza virus. The probes may include further ligands bound to the nanoparticle which do not bind specifically to an influenza virus—for example polyethylene glycol groups. These can modulate density of the glycoconjugate ligand on the surface of the nanoparticle. Binding of probes is detected by a plasmonic signal which is specific to the influenza virus.
    Type: Application
    Filed: July 3, 2014
    Publication date: June 30, 2016
    Inventors: Rob FIELD, Martin REZJEK, Abdul RASHID, David RUSSELL, Maria MARIN